Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to researchers.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to researchers.